
Learn what VCs actually want, from a founder who’s raised $1B
THE SO WHAT
The leverage point in fundraising is moving from pitch quality to metric literacy — messy data and late-stage runway panic are now explicit valuation penalties, not just red flags. Founders should treat finance ops and cohort clarity as go-to-market infrastructure, not back-office hygiene.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureHow AI accounting startup Rillet raised $100M and became a unicorn in 48 hours
A vertical AI accounting startup hitting a $100M round and unicorn status in 48 hours tells you capital is still chasing deep workflow penetration over generic copilots. If you’re in a regulated, repeatable back-office domain, assume specialized AI entrants will get funded to go after your margin structure.
Sources: Devoted Health, which uses AI to help coordinate medical care for those enrolled in Medicare Advantage, is raising new funding at a $25B valuation
A Medicare Advantage-focused care coordination startup reaching a rumored $25B valuation shows how much premium investors put on AI that touches reimbursement and risk scoring. Health operators should expect payer-facing AI workflows—triage, coordination, documentation—to be where capital and regulatory scrutiny concentrate next.
Startups & VentureNvidia to Pay AI Startup Poolside a $6 Billion License, Newcomer Says
A $6 billion model license plus 100+ staff offers from Nvidia is a reminder that differentiated model IP is now a tradeable asset class, not just a product. If you’re training serious models, you need a clear view on who might buy, license, or acqui-hire you long before you think about end-user revenue.
Startups & VentureRunlayer, Rippling drop lawsuits — but the brouhaha is still a cautionary tale for founders
Runlayer and Rippling walking away from lawsuits with no money changing hands — and a competing product launch — underlines that legal fights over talent and IP can mainly serve as market theater. Founders should tighten employment, invention assignment, and data access policies now, so competitive launches are a product problem, not a courtroom one.